Core Viewpoint - Merck & Co., Inc. is seen as undervalued by the market due to concerns over the upcoming patent expiration of Keytruda, but analysts believe there is a clear path for the company to manage this transition and continue to grow [2][3]. Group 1: Analyst Upgrades and Price Target - Deutsche Bank analyst James Shin upgraded Merck from Hold to Buy and raised the price target from $115 to $150, indicating confidence in the company's future despite patent concerns [2]. - The analyst's note suggests that the market is not fully recognizing Merck's potential growth drivers beyond Keytruda [2]. Group 2: Financial Forecasts and Challenges - Merck expects 2026 revenue to be between $65.5 billion and $67.0 billion, which is below the average analyst estimate of $67.6 billion [3]. - The company anticipates a $2.5 billion headwind in 2023 due to generic competition, Medicare price negotiations, and reduced sales of its COVID-19 treatment, Lagevrio [3]. - CEO Rob Davis highlighted that legacy products, particularly Januvia and related treatments, may underperform compared to analyst expectations due to their impending patent expirations [3]. Group 3: Company Overview - Merck operates as a global healthcare company, focusing on prescription medicines, biologic therapies, vaccines, and animal health products, with a significant emphasis on human health treatments [4].

R&D Meeting Overview - The R&D meeting of Sumitomo Pharma Company Limited is being conducted to discuss R&D progress, basic policy, and two major oncology products [1] - The meeting is scheduled to conclude at 15:40 [1] Attendees - Key attendees include Mr. Kimura (Representative Director, President and CEO), Mr. Sakai (Representative Director, Executive Vice President), Ms. Sato (Managing Executive Officer), and Mr. Murata (Global Strategy Oncology Lead) [2] - Mr. Kimura is expected to provide introductory remarks [2]

US FDA approves Vanda's psychiatric drug | ReutersSkip to main content[Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv]Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly//File Photo [Purchase Licensing Rights, opens new tab]- Companies[Vanda Pharmaceuticals Inc]FollowFeb 20 (Reuters) - The U.S. Food and Drug Administration has approved Vanda Pharmaceutical's [(VNDA.O ...

Current Reports on Form 8-K and other filings with the U.S. Securities and Exchange Commission, which are available at [www.sec.gov].All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this press release is ...

Core Viewpoint - Psyence Biomedical Ltd. is advancing its strategic relationship with Psyence Labs Ltd. through the exercise of a put option agreement, which involves an equity investment in PsyLabs to enhance its supply strategy for pharmaceutical-grade psychedelic compounds [1][3][7]. Transaction Overview - Psyence BioMed will acquire equity securities of PsyLabs at a fair market value, with the investment expected to strengthen the strategic alignment between the two companies [3][4]. - The Share-for-Share Exchange will involve PsyLabs issuing 2,900 shares valued at US$5,000,000, while Psyence BioMed will issue 1,146,159 common shares based on a 30-day VWAP of US$4.36 per share [5][6]. - No cash will be exchanged in this transaction, and following the issuance of shares, PsyLabs will own approximately 49.98% of Psyence BioMed's outstanding common shares [6][5]. Strategic Context - The exercise of the put option is seen as a step towards securing high-quality manufacturing capabilities while maintaining capital allocation discipline as Psyence BioMed's development programs progress [7]. Governance - A Special Committee of independent directors reviewed and ratified the transaction, considering the commercial rationale and an independent valuation of PsyLabs [8]. About PsyLabs - PsyLabs is a federally licensed company specializing in the development of psychedelic Active Pharmaceutical Ingredients (APIs), including psilocybin and ibogaine, and has successfully exported products to various countries [9][10]. - The company operates from an ISO 22000-certified facility, ensuring high safety and traceability standards [11]. About Psyence BioMed - Psyence Biomedical Ltd. is a vertically integrated biopharmaceutical company focused on developing nature-derived psychedelic therapeutics, specifically psilocybin and ibogaine, to address unmet mental health needs [11].

Pharmaceutical giant Pfizer (NYSE: PFE) recently had to drop its internally developed GLP-1 weight loss drug candidate. The unfortunate outcome is that the company has had to watch rivals Novo Nordisk and Eli Lilly build early leads in this fast-growing drug niche. With Pfizer facing patent expirations ahead -- and now this GLP-1 setback -- Wall Street remains downbeat on the stock. But that's a potential opportunity for long-term investors. Where to invest $1,000 right now? Our analyst team just reveale ...

Core Insights - The article emphasizes the value of in-depth analysis in the Biotech sector, highlighting the offerings of the Biotech Analysis Central service, which includes a library of over 600 articles and a model portfolio of small and mid-cap stocks [1][2]. Group 1 - The Biotech Analysis Central service is available for $49 per month, with a discounted annual plan at $399, representing a 33.50% savings for subscribers [1]. - The service aims to assist healthcare investors in making informed decisions through comprehensive analysis and news reports [2]. - The author, Terry Chrisomalis, has a background in Applied Science and focuses on generating long-term value in the healthcare sector [2].

Here’s what investors need to know.Mangoceuticals shares are powering higher. Why is MGRX stock surging?TRT Sales Surge 336%Since launching in mid-December, month-over-month sales for the injectable TRT program have climbed 336%, while customer acquisition costs have fallen 54%, the company said in an update. Management expects TRT to be the primary growth driver as MangoRx expands both injectable and oral options, including its PRIME capsule, powered by Kyzatrex.Telehealth Platform Targets Growing TRT Mark ...

Sanofi (NASDAQ:SNY) is one of the Best Dip Stocks to Buy According to Hedge Funds. On February 17, Sanofi (NASDAQ:SNY) announced Manuela Buxo will replace Brian Foard as the Head of its Specialty Care Global Business Unit. Brian Foard, after serving for nearly 9 years, is leaving on February 28 to take on a leadership role elsewhere. ​Manuela Buxo will take over as the Head of Specialty Care Unit on March 1, 2026. She is currently the head of Sanofi’s (NASDAQ:SNY) Global Immunology Alliance Franchise. Fo ...

Olanzapine long-acting injectable (LAI) suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation1If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations1Teva is committed to advancing this innovative treatment option and further building on its differentiated LAI franchise and scientific leadership in complex neurological c ...